{
    "symbol": "CYCC",
    "quarter": 1,
    "year": 2022,
    "date": "2022-05-11 20:45:04",
    "content": " Following receipt after the quarter end of $3.6 million of United Kingdom research and development tax credits and $1.3 million in royalty receipts pro forma March 31, 2022, cash and cash equivalents are $34.5 million. Research and development or R&D expenses were $5 million for the 3 months ended March 31, 2022 as compared to $2.6 million for the same period in 2021. R&D expenses relating to fadraciclib were $3.6 million for the 3 months ended March 31, 2022, as compared to $1.7 million for the same period in 2021 due to increase in clinical trial costs associated with the ongoing clinical trials evaluating fadra in Phase I/II studies along with an increase in non-clinical expenditure. Additionally, R&D expenses related to CYC140 were $1.1 million for the quarter ended March 31, 2022, as compared to $0.7 million for the same period in 2021 due to costs associated with the opening of clinical trial sites and the start of the Phase I/II study, evaluating CYC140 in solid tumors and lymphomas. General and administrative expenses for the 3 months ended March 31, 2022 was $1.6 million compared to $1.7 million in the same period of the previous year due to a decrease in professional and recruitment costs. Total other income net for the quarter ended March 31, 2022, was $1.3 million compared to $0.1 million for the same period of the previous year. United Kingdom research and development tax credits were $1.1 million for the 3 months ending March 31, 2022, as compared to $0.7 million for the same period in 2021 as a direct consequence of increased qualifying R&D expenditure. Net loss for the 3 months ended March 31, 2022, was $4.1 million compared to $3.5 million for the same period in 2021."
}